Dr. Dillon has served as Chief Business Officer since May 2024. She joined ALX Oncology from Calithera Biosciences, where she most recently served as Senior Vice President of Commercial and Portfolio Strategy. Prior to joining Calithera in 2017, Dr. Dillon served in roles of increasing responsibility across marketing, sales, and pipeline commercialization at Genentech. Prior to Genentech, Dr. Dillon was a Senior Consultant at the management consulting firm Campbell Alliance. She completed a Postdoctoral Fellow at the University of California, San Francisco, Howard Hughes Medical Institute, in the now Broad Stem Cell Center. Dr. Dillon holds a Ph.D. and M.S. in Neuroscience from Albert Einstein College of Medicine, and a B.A. in Psychology from the University of Richmond.
